Go to Body

Anterior Pulmonary Ventilation Abnormalities in COVID-19

페이지 정보

작성자 profile_imageadmin 작성일 20-08-14 10:47
63 0



A 66-year-old female patient visited the emergency room due to respiratory distress and was subsequently confirmed positive for coronavirus disease 2019 (COVID-19) using a real-time polymerase chain reaction. At presentation her body temperature was 36.0°C (96.8°F), the white blood cell count and differential were normal with an elevated D-dimer (1371 ng/mL; normal <500 ng/mL). CT pulmonary angiography was performed 2 days after admission showing a few peripheral patchy ground-glass opacities and small areas of consolidation predominantly in both lower lobes (Figure). The percentage extent of COVID-19 pneumonia using freely available MEDIP COVID19 (v1.2.0.0; MEDICALIP Co. Ltd, Seoul, Korea) was 0.93%, and the weight (the percent extent*[CT attenuation + 1000]/1000*1.065g/mL) was 22.5 g (Figure) (1), indicating mild pneumonia. CT pulmonary angiography excluded the presence of pulmonary embolism. The patient was safely discharged home the next day.


(a) CT images and (b-d) pulmonary ventilation map modelled with a full-scale airway network (FAN) flow model in a 66-year-old female with COVID-19 having respiratory distress. (a) Chest CT shows focal consolidation in the right lower lobe and small groundglass opacities in the left lower lobe, (b) CT-based FAN flow model geometry was paired with an AI-driven CT analysis tool, MEDIP COVID19, which labels areas of pneumonia while these areas of pneumonia are marked with yellow spheres in the FAN model. (c, d) Ventilation distribution map computed with the FAN flow model shows a number of regional ventilation defects anteriorly (blue color) where no gross parenchymal lesions existed (not visible) at routine CTA.


Eighty-two patients (mean age, 63.1 ± 14.5 years; 42 females) were included. In the total cohort, male sex (hazard ratio [HR], 9.264; 95% confidence interval [CI], 2.021–42.457; p = 0.004), C-reactive protein (CRP) (HR, 1.080 per mg/dL; 95% CI, 1.010–1.156; p = 0.025), and COVID-affected lung proportion (CALP) (HR, 1.067 per percentage; 95% CI, 1.033–1.101; p < 0.001) were significantly associated with CEFS. CRP (HR, 1.164 per mg/dL; 95% CI, 1.006–1.347; p = 0.041) was independently associated with CEFS in the mild pneumonia group (n = 54). Normally aerated lung proportion (NALP) (HR, 0.872 per percentage; 95% CI, 0.794–0.957; p = 0.004) and NALP volume (NALPV) (HR, 1.002 per mL; 95% CI, 1.000–1.004; p = 0.019) were associated with a lower risk of critical events in the severe pneumonia group (n = 28).

To assess regional lung ventilation in this COVID-19 patient, we used a CT-based full-scale airway network (FAN) flow model. In a prior publication, FAN modelled ventilation showed statistically significant agreements with functional imaging data from chronic obstructive pulmonary disease subjects (2). In this case, we mapped the lesion masks segmented by the MEDIP COVID19 to the FAN model geometry to simulate acinar flow alteration induced by COVID-19 infection. The FAN flow model simulated dynamic airway pressure, flow rate and gas concentration changes to demonstrate the ventilation distribution at full inspiration in COVID-19 (see also the Movie online).

Movie: The FAN flow model simulated dynamic airway pressure, flow rate and gas concentration changes to demonstrate the ventilation distribution at full inspiration in COVID-19.

Download Original Video (9.9 MB)

he FAN flow model showed regional ventilation defects in the upper lobes anteriorly (Figure). The reduced pulmonary ventilation may result from COVID-19-associated airway inflammation beyond CT resolution or microvascular thrombosis (3). Assessing regional ventilation defects may facilitate treatment, monitoring and surveillance of respiratory dysfunction in patients with COVID-19.


The authors gratefully acknowledge the provision of de-identified “COVID data save lives” by HM Hospitales.

  • Company Name ㅣ MEDICALIP
    CEO ㅣ Sang Joon Park    Tel ㅣ +82-2-2135-9148
    Business Registration Number ㅣ 406-81-04085
    Address ㅣ 7F, Changgyeong Building, 174, Yulgok-ro, Jongno-gu, Seoul, Republic of Korea
Copyright2018. MEDICAL IP. All Rights Reserved.